Oncología

Resultados: 87
Tipo Título / Nombre Autor(es) Año
Effectiveness of olaparib plus trastuzumab in HER2[1], BRCA– mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study Alés-Martínez JE, Morales S, Fernández Abad M, Sánchez-Rovira P, Salvador&10, Bofill FJ, et al 2019
Inmunoterapia: largos superviviente y toxicidades más frecuentes Ayala de Miguel P 2019
Diferenciación neuroendocrina de células pequeñas de adenocarcinoma de próstata en paciente con mutación en BRCA-2 Ayala de Miguel P, Gorospe García I, Illán Varella A, López Gallego J, Borrega García P 2019
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, et al 2019
GRADE evaluation of the COLOFOL randomized clinical trial Ceballos E, Robles G 2019
Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study Manso L, Moreno Antón F, Izarzugaza Perón Y, Delgado Mingorance JI, Borrega García P, Echarri González MJ, et al 2019
First - line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer ( mCRC ) patients. PERSEIDA study Topic: cfDNA in mCRC Muñoz Luengo J, García Alfonso P, Valladares Ayerbes M, Pimentel Cáceres P, Viéitez JM, Cruz Hernández JJ, et al 2019
Doxycycline as a preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy: interim analysis to evaluate skin toxicities Ramirez Daffos P, González Astorga B, Jiménez E, Rubiales S, Bolaños M, Ceballos E, et al 2019
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer Romero I, Mallol P, Santaballa A, Del Campo JM, Mori M, González-Santiago S, et al 2019
Interim results from CompLEEment-1 (A phase IIIb study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results Salvador J, Ciruelos E, Jiménez Rodríguez B, Cruz de la L, Villanueva Vázquez R, Toro de R, et al 2019